A share price of Pacific Biosciences of California Inc [PACB] is currently trading at $1.81, up 0.56%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PACB shares have gain 14.56% over the last week, with a monthly amount glided 34.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, JP Morgan downgraded its rating to Neutral on April 22, 2024. On April 18, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $2.50 on the stock. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $11 on December 14, 2023. Guggenheim initiated its recommendation with a Neutral. In a note dated November 17, 2023, UBS upgraded an Buy rating on this stock and revised its target price from $13 to $10.
Pacific Biosciences of California Inc experienced fluctuations in its stock price throughout the past year between $1.16 and $11.95. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Pacific Biosciences of California Inc [NASDAQ: PACB] shares were valued at $1.81 at the most recent close of the market. An investor can expect a potential return of 65.75% based on the average PACB price forecast.
Analyzing the PACB fundamentals
Trailing Twelve Months sales for Pacific Biosciences of California Inc [NASDAQ:PACB] were 188.87M which represents -24.30% decline. Gross Profit Margin for this corporation currently stands at 0.2% with Operating Profit Margin at -1.67%, Pretax Profit Margin comes in at -2.18%, and Net Profit Margin reading is -2.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.61 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7233 points at the first support level, and at 1.6367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9533, and for the 2nd resistance point, it is at 2.0967.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pacific Biosciences of California Inc [NASDAQ:PACB] is 8.01. In addition, the Quick Ratio stands at 7.14 and the Cash Ratio stands at 1.27. Considering the valuation of this stock, the price to sales ratio is 2.61, the price to book ratio is 1.00.
Transactions by insiders
Recent insider trading involved Eidel Jeff, that happened on Aug 19 ’24 when 26760.0 shares were sold., Van Oene Mark completed a deal on Aug 16 ’24 to sell 38011.0 shares. Meanwhile, Officer JEFFREY EIDEL bought 26760.0 shares on Aug 19 ’24.
